ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Cytori Therapeutics, Inc." (CYTX) Report Updated: Aug 22, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Cytori Therapeutics, Inc." (CYTX)

Rating: Sell Volatility: Aggressive
Total Grade: D Industry: Biotechnology
Competitors: MNOV,SPHS,DMPI,EXEL

Stock Analysis

Rating: Monthly View

A
B
C
D
F
August September October November December January February March April May June July

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

"Cytori Therapeutics, Inc."© quotemedia

Company Profile

Cytori Therapeutics, Inc., a biotechnology company, develops cellular therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy consisting of a heterogeneous population of specialized cells, including stem cells for the treatment of patients with scleroderma hand dysfunction, orthopedic disorders, urinary incontinence, and thermal burns combined with radiation injury. It also offers Celution System devices, proprietary enzymes, and sterile consumable sets to commercial customers, as well as for research customers developing new therapeutic applications for Cytori Cell Therapy in Europe, Japan, and other regions. In addition, the company provides StemSource devices, including a cryogenic freezer, measuring and monitoring equipment, and a database patient tracking system, as well as offers consulting, installation, and training services. Cytori Therapeutics, Inc. markets its products to hospitals, clinics, tissue banks, and stem cell banking companies through direct sales reps, distributors, and partners worldwide. The company was founded in 1996 and is headquartered in San Diego, California.